Refractory Malignant Solid Neoplasm Active Not Recruiting Phase 1 / 2 Trials for Crizotinib (DB08865)

IndicationStatusPhase
DBCOND0088735 (Refractory Malignant Solid Neoplasm)Active Not Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00939770Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaTreatment